health
Methylation-based ctDNA test detects head and neck cancer recurrence ahead of clinical examination in 50-patient study
A methylation-based blood test detected recurrence of non-viral head and neck cancer with 76.9% sensitivity and 94.6% specificity, and preceded clinical detection by a median of 131 days in 60% of cases where both occurred. Positive results were strongly associated with worse one-year survival.